155 related articles for article (PubMed ID: 36583540)
1. Vertical integration of oncologists and cancer outcomes and costs in metastatic castration-resistant prostate cancer.
Hu X; Lipscomb J; Jiang C; Graetz I
J Natl Cancer Inst; 2023 Mar; 115(3):268-278. PubMed ID: 36583540
[TBL] [Abstract][Full Text] [Related]
2. The impact of integration on outpatient chemotherapy use and spending in Medicare.
Jung J; Feldman R; Kalidindi Y
Health Econ; 2019 Apr; 28(4):517-528. PubMed ID: 30695812
[TBL] [Abstract][Full Text] [Related]
3. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
Mitchell AP; Mishra Meza A; Panageas KS; Lipitz-Snyderman A; Bach PB; Morris MJ
J Natl Cancer Inst; 2022 Mar; 114(3):419-426. PubMed ID: 34597380
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
[TBL] [Abstract][Full Text] [Related]
5. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
Mitchell AP; Meza AM; Panageas KS; Lipitz-Snyderman A; Farooki A; Morris MJ
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):126-132. PubMed ID: 35798857
[TBL] [Abstract][Full Text] [Related]
6. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
Freedland SJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Ryan CJ
Curr Med Res Opin; 2021 Apr; 37(4):609-622. PubMed ID: 33476184
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model.
Walker B; Frytak J; Hayes J; Neubauer M; Robert N; Wilfong L
JAMA Netw Open; 2020 May; 3(5):e205165. PubMed ID: 32421185
[TBL] [Abstract][Full Text] [Related]
8. Association of Financial Integration Between Physicians and Hospitals With Commercial Health Care Prices.
Neprash HT; Chernew ME; Hicks AL; Gibson T; McWilliams JM
JAMA Intern Med; 2015 Dec; 175(12):1932-9. PubMed ID: 26501217
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations.
Armstrong A; Bui C; Fitch K; Sawhney TG; Brown B; Flanders S; Balk M; Deangelis J; Chambers J
Curr Med Res Opin; 2017 Jun; 33(6):1133-1139. PubMed ID: 28318331
[TBL] [Abstract][Full Text] [Related]
10. Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies.
Manz CR; Tramontano AC; Uno H; Parikh RB; Bekelman JE; Schrag D
JAMA Netw Open; 2022 Sep; 5(9):e2234161. PubMed ID: 36173630
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
[TBL] [Abstract][Full Text] [Related]
12. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
13. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes.
Keating NL; Jhatakia S; Brooks GA; Tripp AS; Cintina I; Landrum MB; Zheng Q; Christian TJ; Glass R; Hsu VD; Kummet CM; Woodman S; Simon C; Hassol A;
JAMA; 2021 Nov; 326(18):1829-1839. PubMed ID: 34751709
[TBL] [Abstract][Full Text] [Related]
14. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
15. A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide.
Woon DTS; Finelli A; Cheung DC; Martin LJ; Alibhai S; Wallis CJD; Diong C; Saskin R; Kulkarni G; Fleshner N
Urology; 2021 Jul; 153():147-155. PubMed ID: 33592224
[TBL] [Abstract][Full Text] [Related]
16. Changes in Opioid Prescribing Patterns Among Generalists and Oncologists for Medicare Part D Beneficiaries From 2013 to 2017.
Agarwal A; Roberts A; Dusetzina SB; Royce TJ
JAMA Oncol; 2020 Aug; 6(8):1271-1274. PubMed ID: 32469405
[TBL] [Abstract][Full Text] [Related]
17. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
18. The value of new drugs for advanced prostate cancer.
Howard DH; Quek RGW; Fox KM; Arondekar B; Filson CP
Cancer; 2021 Sep; 127(18):3457-3465. PubMed ID: 34062620
[TBL] [Abstract][Full Text] [Related]
19. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
20. Where Are the Opportunities for Reducing Health Care Spending Within Alternative Payment Models?
Rocque GB; Williams CP; Kenzik KM; Jackson BE; Halilova KI; Sullivan MM; Rocconi RP; Azuero A; Kvale EA; Huh WK; Partridge EE; Pisu M
J Oncol Pract; 2018 Jun; 14(6):e375-e383. PubMed ID: 28981388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
